欧洲儿童肾脏病学会关于儿童透析患者使用西那卡塞的立场声明
儿童透析患者继发性甲状旁腺功能亢进(SHPT)治疗困难,西那卡塞在成人中有效安全但儿童数据有限。该立场声明基于现有证据和专家意见,提出儿童透析患者使用西那卡塞的推荐,证据强度弱至中等,需个体化应用。
要点
- 西那卡塞可用于常规治疗控制不佳的儿童透析患者SHPT。
- 推荐基于有限证据和专家意见,强度弱至中等。
- 需个体化评估并建议开展审计与研究。
核心结论
- 西那卡塞可用于常规治疗控制不佳的儿童透析患者SHPT,但证据有限,推荐强度弱至中等。
研究设计与样本
- 欧洲儿童肾脏病学会、ERA-EDTA CKD-MBD工作组等基于现有证据和专家意见制定的立场声明。
- 儿童研究包括两项随机对照试验、九项非对照干预或观察性研究及病例报告。
主要发现
- 西那卡塞在成人中有效安全抑制PTH,但儿童数据有限。
- 2017年欧洲药品管理局批准西那卡塞用于透析儿童SHPT常规治疗控制不佳者。
关键数值与推荐
- 推荐条款基于有限证据,强度弱至中等,需治疗医生仔细考虑并个体化调整。
临床怎么用
- 对常规治疗控制不佳的儿童透析SHPT患者,可考虑使用西那卡塞,但需个体化评估。
局限性
- 儿童证据有限,仅两项随机对照试验和九项非对照研究及病例报告。
- 推荐强度弱至中等,需结合个体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Secondary hyperparathyroidism (SHPT) is an important complication of advanced chronic kidney disease (CKD) in children, which is often difficult to treat with conventional therapy. The calcimimetic cinacalcet is an allosteric modulator of the calcium-sensing receptor. It has proven to be effective and safe in adults to suppress parathyroid hormone (PTH), but data on its use in children are limited. To date, studies in children only consist of two randomized controlled trials, nine uncontrolled interventional or observational studies, and case reports that report the efficacy of cinacalcet as a PTH-lowering compound. In 2017, the European Medical Agency approved the use of cinacalcet for the treatment of SHPT in children on dialysis in whom SHPT is not adequately controlled with standard therapy. Since evidence-based guidelines are so far lacking, we present a position statement on the use of cinacalcet in paediatric dialysis patients based on the available evidence and opinion of experts from the European Society for Paediatric Nephrology, Chronic Kidney Disease-Mineral and Bone Disorder and Dialysis Working Groups, and the ERA-EDTA. Given the limited available evidence the strength of these statements are weak to moderate, and must be carefully considered by the treating physician and adapted to individual patient needs as appropriate. Audit and research recommendations to study key outcome measures in paediatric dialysis patients receiving cinacalcet are suggested.
引用
- Bacchetta J, Schmitt CP, Ariceta G, et al. Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA. Nephrol Dial Transplant. 2020. PMID: 31641778. doi:10.1093/ndt/gfz159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。